Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
TMO Stock Forecast 2026-2027
$475.89
Current Price
$176.79B
Market Cap
Buy 23
Hold 4
Sell 0
Wall St Analyst Ratings
Distance to TMO Price Targets
+57.6%
To High Target of $750.00
+40.3%
To Median Target of $667.50
+25.0%
To Low Target of $595.00
TMO Price Momentum
-5.2%
1 Week Change
-5.7%
1 Month Change
-6.5%
1 Year Change
-17.9%
Year-to-Date Change
-26.1%
From 52W High of $643.99
+23.5%
From 52W Low of $385.46
📊 TOP ANALYST CALLS
Did TMO Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Thermo Fisher is one of their latest high-conviction picks.
Latest TMO Stock Price Targets & Analyst Predictions
Based on our analysis of 37 Wall Street analysts, TMO has a bullish consensus with a median price target of $667.50 (ranging from $595.00 to $750.00). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $475.89, the median forecast implies a 40.3% upside. This outlook is supported by 23 Buy, 4 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Paul Knight at Keybanc, projecting a 57.6% upside. Conversely, the most conservative target is provided by Luke Sergott at Barclays, suggesting a 25.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
TMO Analyst Ratings
23
Buy
4
Hold
0
Sell
TMO Price Target Range
Low
$595.00
Average
$667.50
High
$750.00
Current: $475.89
Latest TMO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for TMO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 30, 2026 | Citigroup | Patrick Donnelly | Buy | Maintains | $685.00 |
| Jan 30, 2026 | Barclays | Luke Sergott | Overweight | Maintains | $650.00 |
| Jan 30, 2026 | TD Cowen | Dan Brennan | Buy | Maintains | $683.00 |
| Jan 9, 2026 | Stifel | Daniel Arias | Buy | Maintains | $700.00 |
| Jan 7, 2026 | TD Cowen | Dan Brennan | Buy | Maintains | $696.00 |
| Dec 15, 2025 | Wells Fargo | Brandon Couillard | Overweight | Maintains | $675.00 |
| Dec 11, 2025 | Citigroup | Patrick Donnelly | Buy | Upgrade | $660.00 |
| Dec 9, 2025 | Goldman Sachs | Evie Koslosky | Buy | Initiates | $685.00 |
| Dec 8, 2025 | Keybanc | Paul Knight | Overweight | Upgrade | $750.00 |
| Dec 2, 2025 | Morgan Stanley | Tejas Savant | Overweight | Maintains | $670.00 |
| Dec 1, 2025 | HSBC | Sidharth Sahoo | Buy | Upgrade | $670.00 |
| Oct 29, 2025 | Argus Research | David Toung | Buy | Maintains | $610.00 |
| Oct 28, 2025 | Morgan Stanley | Tejas Savant | Overweight | Maintains | $656.00 |
| Oct 23, 2025 | Citigroup | Patrick Donnelly | Neutral | Maintains | $580.00 |
| Oct 23, 2025 | Barclays | Luke Sergott | Overweight | Maintains | $625.00 |
| Oct 23, 2025 | TD Cowen | Dan Brennan | Buy | Maintains | $654.00 |
| Oct 23, 2025 | UBS | Dan Leonard | Neutral | Maintains | $590.00 |
| Oct 23, 2025 | Wells Fargo | Brandon Couillard | Overweight | Maintains | $635.00 |
| Oct 22, 2025 | Leerink Partners | Puneet Souda | Outperform | Maintains | $580.00 |
| Oct 9, 2025 | JP Morgan | Casey Woodring | Overweight | Maintains | $650.00 |
Thermo Fisher Scientific Inc. (TMO) Competitors
The following stocks are similar to Thermo Fisher based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
TMO
Thermo Fisher
mkt cap
188.59B
Thermo Fisher Scientific Inc. (TMO) Financial Data
Thermo Fisher Scientific Inc. has a market capitalization of $176.79B with a P/E ratio of 27.9x. The company generates $44.56B in trailing twelve-month revenue with a 15.0% profit margin.
Revenue growth is +7.2% quarter-over-quarter, while maintaining an operating margin of +21.2% and return on equity of +13.0%.
Valuation Metrics
Market Cap
$176.79B
Enterprise Value
$215.54B
P/E Ratio
27.9x
PEG Ratio
3.1x
Price/Sales
4.1x
Growth & Margins
Revenue Growth (YoY)
+7.2%
Gross Margin
+41.0%
Operating Margin
+21.2%
Net Margin
+15.0%
EPS Growth
+7.3%
Financial Health
Cash/Price Ratio
+5.7%
Current Ratio
1.9x
Debt/Equity
77.3x
ROE
+13.0%
ROA
+5.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Thermo Fisher Scientific Inc. (TMO) Business Model
About Thermo Fisher Scientific Inc.
What They Do
Provides life sciences and analytical solutions.
Business Model
The company generates revenue by offering a wide range of products and services, including life sciences solutions, analytical instruments, and laboratory products. It serves a diverse customer base, including pharmaceutical companies, hospitals, and research institutions, through both direct sales and global distribution networks.
Additional Information
Headquartered in Waltham, Massachusetts, Thermo Fisher Scientific operates internationally, supporting customers in North America, Europe, and Asia-Pacific. Its portfolio includes well-known brands such as Fisher Scientific and services through Patheon and PPD, enhancing its position in the biopharma sector.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
125,000
CEO
Mr. Marc N. Casper
Country
United States
IPO Year
1987
Website
www.thermofisher.comThermo Fisher Scientific Inc. (TMO) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
PacBio and DNAstack Collaborate on Global HiFi Genome Network Hub
PACB teams with DNAstack to launch a global HiFi genome network, linking 10,000+ sequences to boost rare disease research without moving data.
Mar 03, 2026
By Zacks Equity Research
Analyst Blog
Latest News
Quick Summary
TMO's growth is bolstered by acquisitions and strong demand in pharma, biotech, and diagnostics, but faces risks from currency fluctuations and intense competition.
Why It Matters
TMO's growth prospects are bolstered by acquisitions and strong market demand, yet currency fluctuations and competition could impact profitability and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Thermo Fisher Scientific has opened a Cryo-Electron Microscopy Drug Discovery Center in South San Francisco, enhancing access to cryo-EM technology for pharmaceutical and biotech companies.
Why It Matters
The opening of Thermo Fisher's Cryo-EM Drug Discovery Center enhances its competitive edge in biotech, potentially boosting revenue from increased partnerships and accelerated drug development.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Thermo Fisher Scientific Inc. (TMO) presented at the 47th Annual Raymond James Institutional Investor Conference, sharing insights and updates relevant for investors.
Why It Matters
Thermo Fisher's presentation may provide insights into its financial performance, growth strategies, and market outlook, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Thermo Fisher Scientific launched new chromogenic culture media for rapid detection of Candida species, addressing the rising threat of antimicrobial resistance in healthcare.
Why It Matters
The launch of new culture media by Thermo Fisher Scientific addresses the rising threat of antimicrobial resistance, positioning the company to capitalize on growing healthcare demands and potential revenue growth.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Thermo Fisher Scientific is rated a 'buy' with a $619/share fair value. The $8.875B acquisition of Clario Holdings aims to boost revenue and growth, with FY26 forecasts of 3%-4% revenue growth and 6%-8% EPS growth.
Why It Matters
Thermo Fisher's strong buy rating and fair value estimate signal confidence in growth potential, enhanced by the Clario acquisition and positive revenue projections, attracting investor interest.
Source: Seeking Alpha
Market Sentiment:
Positive
Baron Health Care Fund Q4 2025 Recent Activity
10 days ago
Quick Summary
Baron Health Care Fund added seven new positions and exited ten, totaling 43. It bought Arcutis Biotherapeutics and sold Cidara Therapeutics post-acquisition by Merck.
Why It Matters
Baron Health Care Fund's strategic shifts indicate confidence in new biotech opportunities while capitalizing on acquisition premiums, reflecting changing market dynamics and potential investment returns.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About TMO Stock
What is Thermo Fisher Scientific Inc.'s (TMO) stock forecast for 2026?
Based on our analysis of 37 Wall Street analysts, Thermo Fisher Scientific Inc. (TMO) has a median price target of $667.50. The highest price target is $750.00 and the lowest is $595.00.
Is TMO stock a good investment in 2026?
According to current analyst ratings, TMO has 23 Buy ratings, 4 Hold ratings, and 0 Sell ratings. The stock is currently trading at $475.89. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for TMO stock?
Wall Street analysts predict TMO stock could reach $667.50 in the next 12 months. This represents a 40.3% increase from the current price of $475.89. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Thermo Fisher Scientific Inc.'s business model?
The company generates revenue by offering a wide range of products and services, including life sciences solutions, analytical instruments, and laboratory products. It serves a diverse customer base, including pharmaceutical companies, hospitals, and research institutions, through both direct sales and global distribution networks.
What is the highest forecasted price for TMO Thermo Fisher Scientific Inc.?
The highest price target for TMO is $750.00 from Paul Knight at Keybanc, which represents a 57.6% increase from the current price of $475.89.
What is the lowest forecasted price for TMO Thermo Fisher Scientific Inc.?
The lowest price target for TMO is $595.00 from Luke Sergott at Barclays, which represents a 25.0% increase from the current price of $475.89.
What is the overall TMO consensus from analysts for Thermo Fisher Scientific Inc.?
The overall analyst consensus for TMO is bullish. Out of 37 Wall Street analysts, 23 rate it as Buy, 4 as Hold, and 0 as Sell, with a median price target of $667.50.
How accurate are TMO stock price projections?
Stock price projections, including those for Thermo Fisher Scientific Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: March 13, 2026 6:07 PM UTC